Metabolic
Diseases
Product Candidates
Disease/Condition
Mechanism
Partner
Our Commercial Rights
Status
MB07803
Diabetes
FBPase
Inhibitor
None
Worldwide
Phase 2
MB07811
Hyperlipidemia
TRβ Agonist
None
Worldwide
Phase 1b
Undisclosed
Diabetes
Glucagon Antagonist
None
Worldwide
Preclinical
Undisclosed
Hyperlipidemia
TRβ Agonist
None
Worldwide
Preclinical
Undisclosed
Diabetes/
Hyperlipidemia
AMPK Activators
Merck
Royalties,
North America
Co-promotion Option
Preclinical
Liver Diseases
Product Candidates
Disease/Condition
Mechanism
Partner
Our Commercial Rights
Status
MB07133
Primary Liver Cancer
Prodrug of activated cytarabine
None
Worldwide
Phase 1/2 completed
Pradefovir
Hepatitis B
Prodrug of adefovir
None
Worldwide
Phase 2b completed
Undisclosed
[1]
HCV
Undisclosed
Merck
Idenix
Royalties
Discovery
[1]
Metabasis liver targeting technology applied to partners’ candidate compounds.
Web Site Terms of Use
|
Web Site Privacy Policy
|
Forward-Looking Statements
©2008 Copyright, Metabasis Therapeutics, Inc. San Diego, CA
